About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...

Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – ...

This submission follows positive Phase 3 trial results from the VERITAC-2 study, which highlighted the drug’s efficacy against fulvestrant. The study’s findings were presented at the American Society ...

This submission follows promising results from the Phase 3 VERITAC-2 trial, which showed a median progression-free survival of five months for vepdegestrant compared to 2.1 months in the control group ...

This submission follows positive Phase 3 trial results from the VERITAC-2 study, which highlighted the drug’s efficacy against fulvestrant.

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and ...

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published ...